Healthcare · Biotechnology
Price
$8.44
Market Cap
$838.1M
Employees
155
Beta
0.83
Avg Volume
1,754,888
CEO
Richard E. Lowenthal
Business Description
ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.
Business History
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-4.85
Stock Price: $8.44
EPS (Diluted): -1.74
EPS (Diluted): -1.74
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
10.05
Stock Price: $8.44
Total Equity: $114.26M
Shares: 98,566,481
Total Equity: $114.26M
Shares: 98,566,481
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-7.19
Market Cap: $838.12M
Total Debt: $96.37M
Cash: $41.32M
EBITDA: -$167.41M
Total Debt: $96.37M
Cash: $41.32M
EBITDA: -$167.41M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$1.2B
Market Cap: $838.12M
Total Debt: $96.37M
Cash: $41.32M
Total Debt: $96.37M
Cash: $41.32M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
13.63
Stock Price: $8.44
Revenue: $84.28M
Shares: 98,566,481
Revenue: $84.28M
Shares: 98,566,481
EV/Sales (Total value vs revenue — works when P/E can't)
API14.28
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
75.8%
Gross Profit: $63.86M
Revenue: $84.28M
Revenue: $84.28M
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
-212.9%
Operating Income: -$179.45M
Revenue: $84.28M
Revenue: $84.28M
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
-203.3%
Net Income: -$171.30M
Revenue: $84.28M
Revenue: $84.28M
ROE (Profit from shareholder equity)
CALCNet Income / Total Equity
-149.9%
Net Income: -$171.30M
Total Equity: $114.26M
Total Equity: $114.26M
ROIC (Profit from all invested capital)
CALCNOPAT / Invested Capital
-105.9%
Operating Income: -$179.45M
Tax Rate: 0.0%
Equity: $114.26M
Total Debt: $96.37M
Cash: $41.32M
Tax Rate: 0.0%
Equity: $114.26M
Total Debt: $96.37M
Cash: $41.32M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
7.28
Current Assets: $284.90M
Current Liabilities: $39.15M
Current Liabilities: $39.15M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.84
Short-Term Debt: $0.00
Long-Term Debt: $96.37M
Total Debt: $96.37M
Total Equity: $114.26M
Long-Term Debt: $96.37M
Total Debt: $96.37M
Total Equity: $114.26M
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$0.86
Revenue: $84.28M
Shares: 98,566,481
Shares: 98,566,481
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$1.16
Total Equity: $114.26M
Shares: 98,566,481
Shares: 98,566,481
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-1.74
Operating CF: -$170.87M
CapEx: -$339,000
Shares: 98,566,481
CapEx: -$339,000
Shares: 98,566,481
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $8.44
Stock Price: $8.44
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$171.30M
Net Income: -$171.30M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares SPRY against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 26, 2026 4:47pm (16h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $5.5M | $1.3M | $30,000 | $89.1M | $84.3M |
| Cost of Revenue | $213,000 | $17.1M | $0 | $20.6M | $20.4M |
| Gross Profit | $5.3M | -$15.8M | $30,000 | $68.6M | $63.9M |
| Operating Expenses | $24.7M | $19.7M | $67.6M | $71.7M | $243.3M |
| Operating Income | -$19.5M | -$35.5M | -$67.5M | -$3.1M | -$179.4M |
| Net Income | -$20.2M | -$34.7M | -$54.4M | $8.0M | -$171.3M |
| EBITDA | -$19.9M | -$34.4M | -$54.3M | $8.4M | -$167.4M |
| EPS | $-0.70 | $-0.87 | $-0.57 | $0.08 | $-1.74 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 26, 2026 4:47pm (16h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $60.1M | $210.5M | $71.0M | $50.8M | $41.3M |
| Total Current Assets | $60.7M | $277.7M | $231.6M | $334.3M | $284.9M |
| Total Assets | $61.4M | $281.4M | $233.2M | $351.2M | $327.7M |
| Current Liabilities | $8.2M | $5.4M | $2.4M | $23.4M | $39.1M |
| Long-Term Debt | $4.9M | $0 | $0 | $0 | $96.4M |
| Total Liabilities | $92.7M | $8.5M | $2.4M | $94.4M | $213.4M |
| Total Equity | -$31.3M | $272.9M | $230.8M | $256.8M | $114.3M |
| Retained Earnings | -$42.3M | -$76.9M | -$131.3M | -$123.3M | -$294.6M |
Cash Flow (Annual)
Last updated: Jun 26, 2026 4:47pm (16h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$17.6M | -$40.1M | -$59.3M | $13.5M | -$170.9M |
| Capital Expenditure | $-55,000 | $-199,000 | $-175,000 | $-563,000 | $-339,000 |
| Free Cash Flow | -$17.6M | -$40.3M | -$59.4M | $13.0M | -$171.2M |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $35.5M | $150.5M | -$139.5M | -$20.2M | -$9.5M |
Analyst Estimates (Annual)
Last updated: Jun 26, 2026 4:47pm (16h ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$273.7M $252.5M – $302.0M
|
$445.8M $439.8M – $451.9M
|
$585.8M $513.7M – $646.8M
|
$638.6M $559.9M – $705.1M
|
| EBITDA |
-$213.8M -$235.9M – -$197.2M
|
-$348.3M -$353.0M – -$343.6M
|
-$457.7M -$505.3M – -$401.3M
|
-$498.9M -$550.8M – -$437.4M
|
| Net Income |
-$98.3M -$115.9M – -$70.7M
|
$4.2M -$191.3M – $131.4M
|
$56.2M $47.2M – $63.8M
|
$67.5M $56.7M – $76.6M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 26, 2026 4:47pm (16h ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -76.1% | -97.7% | +297,063.3% | -5.5% |
| Gross Profit Growth | -398.6% | +100.2% | +228,540.0% | -6.9% |
| Operating Income Growth | -82.6% | -90.1% | +95.4% | -5,720.6% |
| Net Income Growth | -71.3% | -56.8% | +114.7% | -2,241.8% |
| EBITDA Growth | -72.5% | -58.0% | +115.4% | -2,101.3% |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for SPRY — it's generated by the pipeline (
market-narrative step).
No community reviews yet for SPRY.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30